GlassScriptPhysician profile
Ellen Matteson
NPI 1427320282
$3,432.30
in general payments reported to CMS, 2019-2025
24 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $680 · 2023: $794 · 2024: $586 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.25 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $645.18 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $446.93 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $326.63 | 2021-2025 | Ilumya |
| Pfizer INC. | $257.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $224.69 | 2021-2025 | |
| Incyte Corporation | $214.07 | 2021-2025 | Opzelura |
| Almirall LLC | $184.98 | 2023-2025 | Klisyri |
| Galderma Laboratories, L.P. | $180.92 | 2021-2024 | |
| Genzyme Corporation | $114.53 | 2023-2025 | |
| Leo Pharma INC. | $95.35 | 2021-2025 | Anzupgo |
| Regeneron Healthcare Solutions, INC. | $89.08 | 2021 | |
| Ucb, INC. | $74.31 | 2022-2025 | Bimzelx |
| Dermavant Sciences, INC. | $72.74 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $70.73 | 2024 | Sotyktu |
| Journey Medical Corporation | $66.72 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.48 | 2021-2022 | |
| Amgen INC. | $62.74 | 2023-2025 | Otezla, Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $53.61 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $51.63 | 2022 | |
| Dermira, INC. | $38.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2024 | Spevigo |
| Organon LLC | $28.46 | 2025 | Hadlima |
| Botanix Sb INC | $25.59 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $11.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Matteson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.